Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11773147 Lipocalin muteins with binding affinity for LAG-3

Patent 11773147 was granted and assigned to Pieris Pharmaceuticals on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Pieris Pharmaceuticals
Pieris Pharmaceuticals
Date Filed
October 12, 2021
Date of Patent
October 3, 2023
Patent Application Number
17499640
Patent Citations
‌
US Patent 10501510 Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof
‌
US Patent 9522940 Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
‌
US Patent 10526384 Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
‌
US Patent 7585940 Muteins of human tear lipocalin
‌
US Patent 7893208 Muteins of human tear lipocalin
‌
US Patent 9212208 Muteins with tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the same
Patent Inventor Names
Rachida Siham Bel Aiba
Christine Rothe
Marina Pavlidou
Shane Olwill
Andrea Allersdorfer
Timo Eichner
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11773147
Patent Primary Examiner
‌
Christina Bradley

Find more entities like US Patent 11773147 Lipocalin muteins with binding affinity for LAG-3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo